Syros Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SYRS research report →
About the company
Syros Pharmaceuticals, Inc. operates as a biopharmaceutical firm primarily focused on discovering and developing novel therapeutic solutions for various cancers and monogenic (single-gene) diseases. A key strategic aim for the company involves cultivating a robust pipeline of medicines that modulate gene expression.
- CEO
- James E. Bradner
- IPO
- 2016
- Employees
- 68
- HQ
- Cambridge, MA, US
Price Chart
- Market Cap
- $2.68K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 0.49
- Div Yield
- 0.00%
- Gross Margin
- 77.33%
- Op Margin
- -1298.19%
- Net Margin
- -1656.34%
- ROE
- -227.94%
- ROIC
- -91.82%
- Revenue
- $9.94M · -33.23%
- Net Income
- $-164,574,000 · -73.87%
- EPS
- $-5.81 · 22.43%
- Op Income
- $-128,988,000
- FCF YoY
- 11.53%
- 52W High
- $0.04
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 1.27
- Avg Volume
- 11.54K
Get TickerSpark's AI analysis on SYRS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 2, 24 | Simonian Nancy A | sell | 37,070 |
| Nov 25, 24 | Simonian Nancy A | sell | 134,713 |
| Nov 18, 24 | Stephens Kristin | sell | 36,133 |
| Nov 18, 24 | Roth David | sell | 12,099 |
| Nov 19, 24 | Quirk Gerald E | sell | 46,657 |
| Nov 18, 24 | Chee Conley | sell | 134,797 |
| Nov 18, 24 | Haas Jason | sell | 137,803 |
| Oct 31, 24 | Simonian Nancy A | other | 40,125 |
| Oct 31, 24 | Simonian Nancy A | other | 40,125 |
| Oct 31, 24 | Roth David | other | 18,875 |
Our SYRS coverage
Recent articles, reports, and earnings notes.
No research on SYRS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SYRS report →Similar companies
Peers in the same neighborhood.